Mark C Markowski

List of Publications by Year
in descending order

37	914	471509 17	477307 29
papers	citations	h-index	g-index

39	39	39	1492
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum, 2020, 4, pkz093.	2.9	126
2	The Microbiome and Genitourinary Cancer: A Collaborative Review. European Urology, 2019, 75, 637-646.	1.9	103
3	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 1371-1382.	1.6	65
4	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	1.9	61
5	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology, 2021, 79, 692-699.	1.9	49
6	Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT. Molecular Imaging and Biology, 2019, 21, 567-573.	2.6	46
7	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	3.0	42
8	BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?. Journal of Clinical Oncology, 2020, 38, 3735-3739.	1.6	38
9	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology Biology Physics, 2019, 105, 948-956.	0.8	37
10	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. Cancer Research, 2021, 81, 5948-5962.	0.9	30
11	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate, 2016, 76, 1484-1490.	2.3	29
12	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer, 2021, 144, 302-309.	2.8	29
13	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. Expert Opinion on Investigational Drugs, 2017, 26, 1391-1397.	4.1	26
14	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Clinical Genitourinary Cancer, 2019, 17, 470-475.e1.	1.9	26
15	Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. Prostate, 2020, 80, 407-411.	2.3	24
16	Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigenâ€“Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. Journal of Nuclear Medicine, 2021, 62, 1430-1437.	5.0	24
17	Early use of chemotherapy in metastatic prostate cancer. Cancer Treatment Reviews, 2017, 55, 218-224.	7.7	19
18	A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptorâ€“targeting Agent. Clinical Cancer Research, 2022, 28, 2789-2795.	7.0	17

#	Article	IF	Citations
19	A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). BMC Cancer, 2020, 20, 492.	2.6	16
20	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer, 2022, 20, 97-101.	1.9	14
21	The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine, 2022, 63, 248-252.	5.0	13
22	Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. Journal of Urology, 2020, 204, 496-502.	0.4	12
23	Advanced renal cell carcinoma and COVID-19 â€" a personal perspective. Nature Reviews Urology, 2020, 17, 425-427.	3.8	10
24	Germline Genetic Testing in Prostate Cancer â€“ Further Enrichment in Variant Histologies?. Oncoscience, 2018, 5, 62-64.	2.2	7
25	Detection of Early Progression with ¹⁸F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy. Journal of Nuclear Medicine, 2021, 62, 1270-1273.	5.0	6
26	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸F-DCFPyL. Molecular Imaging, 2022, 2022, 7056983.	1.4	6
27	Bipolar androgen therapy (BAT): A patient's guide. Prostate, 2022, 82, 753-762.	2.3	6
28	Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes. Urology, 2021, 154, 201-207.	1.0	5
29	Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: AÂCase Report. Clinical Genitourinary Cancer, 2017, 15, e839-e842.	1.9	4
30	Characterization of novel cell lines derived from a MYCâ€driven murine model of lethal metastatic adenocarcinoma of the prostate. Prostate, 2018, 78, 992-1000.	2.3	4
31	PARP inhibitors in prostate cancer: time to narrow patient selection?. Expert Review of Anticancer Therapy, 2020, 20, 523-526.	2.4	4
32	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. Journal of Urology, 2021, 206, 623-629.	0.4	4
33	Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. European Urology Open Science, 2022, 41, 112-115.	0.4	4
34	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer, 2019, 19, 572.	2.6	3
35	Cutaneous finger and tongue metastases in renal cell carcinoma. BMJ Case Reports, 2019, 12, e230516.	0.5	2
36	Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate Cancer. Clinical Genitourinary Cancer, 2016, 14, e417-e422.	1.9	0

#	Article	IF	Citations
37	Abstract 2404: Increased mitochondrial DNA copy number occurs during prostate cancer progression and in cancer precursor lesions across multiple organs. , 2021, , .		0